Function-first antibody discovery Embracing the unpredictable biology of antibodies

OncoImmunology

Volumn 2, Issue 8, 2013, Pages

  Frendéus, Björn ^a  

^a BioInvent International AB   (Sweden)

Author keywords

Antibody biology; Antibody discovery; Cancer; Drug development; Function first; ICAM 1; IRST; Myeloma; Target discovery; Therapeutic antibody

Indexed keywords

ANTINEOPLASTIC AGENT; BI 505; CANCER ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; OBINUTUZUMAB; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; BIOACCUMULATION; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; MOLECULAR DYNAMICS; MULTIPLE MYELOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 84885794229     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25047     Document Type: Article

References (10)

1. Veitonmäki N, Hansson M, Zhan F, Sundberg A, Löfstedt T, Ljungars A, et al. A human icam-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell 2013; 23:502-15; PMID:23597564; http://dx.doi.org/10.1016/j.ccr.2013.02.026
2. Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen TH, Srinivasan M, et al. Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells. Cancer Immunol Res 2013; http://dx.doi. org/10.1158/2326-6066.CIR-13-0013
3. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010; 18:160-70; PMID:20708157; http://dx.doi.org/10.1016/j. ccr.2010.06.014
4. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443-6; PMID:10742152; http://dx.doi.org/10.1038/74704
5. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/ neu-positive metastatic breast cancer. J Clin Oncol 2008; 26:1789-96; PMID:18347005; http://dx.doi. org/10.1200/JCO.2007.14.8957
6. Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011; 117:4519-29; PMID:21378274; http://dx.doi.org/10.1182/ blood-2010-07-296913
7. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004; 103:2738-43; PMID:14551143; http:// dx.doi.org/10.1182/blood-2003-06-2031
8. Fransson J, Tornberg UC, Borrebaeck CA, Carlsson R, Frendéus B. Rapid induction of apoptosis in B-cell lymphoma by functionally isolated human antibodies. Int J Cancer 2006; 119:349-58; PMID:16477633; http://dx.doi.org/10.1002/ijc.21829
9. Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 2009; 114:3625-8; PMID:19710503; http://dx.doi. org/10.1182/blood-2009-05-220285
10. Zheng Y, Yang J, Qian J, Qiu P, Hanabuchi S, Lu Y, et al. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia 2013; 27:702-10; PMID:22996336; http://dx.doi.org/10.1038/ leu.2012.272